Analysts predict that Karyopharm Therapeutics (NASDAQ:KPTI) will post sales of $4.59 million for the current quarter, according to Zacks. Four analysts have issued estimates for Karyopharm Therapeutics’ earnings. The highest sales estimate is $15.00 million and the lowest is $50,000.00. Karyopharm Therapeutics posted sales of $70,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 6,457.1%. The firm is expected to report its next earnings report on Thursday, May 3rd.
On average, analysts expect that Karyopharm Therapeutics will report full-year sales of $13.98 million for the current fiscal year, with estimates ranging from $200,000.00 to $30.00 million. For the next year, analysts anticipate that the company will post sales of $19.50 million per share, with estimates ranging from $6.61 million to $45.41 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, March 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.14). The company had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $2.26 million. During the same period in the prior year, the firm posted ($0.65) EPS. The company’s revenue was up 3163.8% compared to the same quarter last year.
Several equities research analysts recently issued reports on KPTI shares. Canaccord Genuity restated a “buy” rating and set a $22.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, April 10th. BidaskClub cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 3rd. JPMorgan Chase raised their price objective on shares of Karyopharm Therapeutics from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 10th. Leerink Swann reiterated an “outperform” rating and set a $19.00 price target on shares of Karyopharm Therapeutics in a research report on Monday, April 2nd. Finally, Zacks Investment Research cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 21st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. Karyopharm Therapeutics has a consensus rating of “Buy” and a consensus target price of $20.20.
In related news, CEO Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $14.79, for a total value of $147,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christopher Brett Primiano sold 2,500 shares of Karyopharm Therapeutics stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.01, for a total transaction of $37,525.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 69,000 shares of company stock valued at $999,625. Company insiders own 14.71% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. grew its holdings in shares of Karyopharm Therapeutics by 21.0% in the third quarter. Schwab Charles Investment Management Inc. now owns 140,360 shares of the company’s stock valued at $1,542,000 after purchasing an additional 24,324 shares in the last quarter. Palo Alto Investors LLC lifted its stake in Karyopharm Therapeutics by 1.3% in the fourth quarter. Palo Alto Investors LLC now owns 3,544,439 shares of the company’s stock worth $34,027,000 after acquiring an additional 45,854 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Karyopharm Therapeutics by 172.7% in the fourth quarter. Alliancebernstein L.P. now owns 118,430 shares of the company’s stock worth $1,137,000 after acquiring an additional 75,000 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in Karyopharm Therapeutics in the fourth quarter worth approximately $115,000. Finally, Franklin Resources Inc. lifted its stake in Karyopharm Therapeutics by 6.4% in the fourth quarter. Franklin Resources Inc. now owns 3,337,569 shares of the company’s stock worth $32,041,000 after acquiring an additional 200,310 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.
Karyopharm Therapeutics stock traded down $0.18 during midday trading on Wednesday, hitting $14.59. 708,358 shares of the stock were exchanged, compared to its average volume of 578,134. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $18.00. The stock has a market cap of $733.37, a P/E ratio of -5.19 and a beta of 3.61.
ILLEGAL ACTIVITY WARNING: “Karyopharm Therapeutics (KPTI) Expected to Announce Quarterly Sales of $4.59 Million” was first posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://macondaily.com/2018/04/21/karyopharm-therapeutics-kpti-expected-to-announce-quarterly-sales-of-4-59-million.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.